Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT02535156

Schizotypal Personality Disorder Risperidone

Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Conditions Schizotypal Personality Disorder

Updated 6 times since 2017 Last updated: Aug 10, 2017 Started: Jan 31, 2003 Primary completion: Jan 31, 2014 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Schizotypal Personality Disorder and is currently completed. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Sep 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Sep 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Data source: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.